's general knowledge of influence factor of the cancer prognosis of pancreas

's general knowledge of influence factor of the cancer prognosis of pancreas
A research shows, human macrophage metal elastic protease(HME)s It relates to the fact that the cancer prognosis of pancreas worsens to cross and express. Dr. Peter Balaz of Germany Heidelberg university points out, HME is ground substance metal protease (MMP) Each,as elastin, various ground substance with having something to do by ground substance the degradations of substrate, this material has already been found in skin carcinoma, star cell tumour, colloid master cell tumour and hepatocarcinoma. Researchers measure 39 pancreas cancers, 13 normal edition with parallel text and HME of 16 cases of pancreatitis to express, analyze the relation with clinical pathologic parameter and time of surviving. Found finally, detected very low HME mRNA to express while organizing normally, the immune group measured negatively. Pancreas cancer HME mRNA rises 41 times, among them, in 18 (56%) Pancreas cancer sample, 20 (63%) Ground substance cell sample and 8 (25%) The immune groups HME are intermediate and positive in pancreas cancer ground substance cell sample. Chronic HME mRNA of pancreatitis express 3 to 16 times of increasing, 3 organize the sample HME immune group masculine gender normally only. HME mRNA positive patient's average life cycle is 11.5 months, prominent 22 months less than negative patient. Adopt single variable and relevant analysis to find, HME is positive to lead with patient's age, gender, tumour size, by stages, shift the lymph node and have nothing to do in grades. In addition, researchers also find that can be measured and expressed in 5 kinds of human pancreas cancer cell one to HME mRNA too. Researchers infer, HME may stimulate growth and blood vessel of the pancreas cancer cell to infringe, but will not influence the lymph node to shift, take shape. Non- alternative ground substance metal protease inhibitor entering the clinical trial now has already embodied function which has improved the cancer prognosis of early pancreas, and alternative inhibitor can be by the specific progress of acting on pancreas cancer. Dr. Balaz thinks, the treatment of pancreas cancer should include HME inhibits, develops treatment means that alternative MMP inhibitor will increase pancreas cancer.
|